Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A two-part study in Japanese patients with advanced or metastatic NSCL [non-small cell lung cancer]. Open-label phase I to assess the safety and tolerability of AZD2171 [cediranib] in combination with pac/carb [paclitaxel/carboplatin], then a phase II, randomised, double-blind study to assess the efficacy of AZD2171 alone and in combination with pac/carb

Next Previous
X
Search
Trial Profile

A two-part study in Japanese patients with advanced or metastatic NSCL [non-small cell lung cancer]. Open-label phase I to assess the safety and tolerability of AZD2171 [cediranib] in combination with pac/carb [paclitaxel/carboplatin], then a phase II, randomised, double-blind study to assess the efficacy of AZD2171 alone and in combination with pac/carb

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cediranib (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

    • Most Recent Events

    • 07 Dec 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Additional lead trial investigator Jane Robertson identified as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Actual end date (1 Jul 2008) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top